Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on the research, development, and commercialization of a unique radiation therapy technology called diffusing alpha-emitters radiation therapy (Alpha DaRT). This technology is designed to treat solid cancers by delivering alpha radiation directly to tumors. Alpha Tau is currently conducting clinical trials for various cancer types, including skin, oral, pancreatic, prostate, lung, liver, and breast cancers. Additionally, the company has preclinical studies for mouse tumors and human-derived tumors. Alpha Tau also has a strategic collaboration agreement to develop and commercialize Alpha DaRT specifically for prostate cancer treatment. The company is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol DRTS. The trading currency for its shares is the US Dollar (USD). The company's region is designated as 'us', indicating its primary listing in the United States, although its headquarters are in Israel.

Alpha Tau Medical Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies for cancer treatment. The company's primary focus is on its proprietary Alpha DaRT technology, which is a form of radiation therapy that uses diffusing alpha-emitters to target solid tumors. This places Alpha Tau at the intersection of oncology therapeutics and advanced radiation technology.

Alpha Tau Medical Ltd. is headquartered in Jerusalem, Israel. While the company is based in Israel, its primary stock listing is on the NasdaqCM in the United States, indicating a focus on the US capital markets. The company's clinical trials and development efforts target a global patient population, with studies covering various cancers such as skin, oral, pancreatic, prostate, lung, liver, and breast cancers. Additionally, Alpha Tau has a strategic collaboration agreement to develop and commercialize its Alpha DaRT technology for prostate cancer, which may expand its market reach.

Alpha Tau Medical Ltd. is a clinical-stage company, meaning it has not yet commercialized its products and currently does not generate revenue from product sales. Its business model revolves around the research, development, and eventual commercialization of its Alpha DaRT technology. The company is conducting clinical trials to demonstrate the safety and efficacy of Alpha DaRT for various solid cancers. Once approved by regulatory authorities, Alpha Tau plans to generate revenue by offering Alpha DaRT as a treatment option to healthcare providers. The company also has a strategic collaboration agreement focused on prostate cancer, which may involve licensing or partnership fees. As a clinical-stage biotechnology firm, Alpha Tau's primary activities include R&D, clinical trials, and seeking regulatory approvals.